Skip to Content

Join the 'Cushing's Syndrome' group to help and get support from people like you.

Cushing's Syndrome News

Related terms: Cushing's Syndrome, ectopic, Cushing's Syndrome, exogenous

Signifor Approved for Cushing's Disease

Posted 17 Dec 2012 by Drugs.com

MONDAY, Dec. 17 – Signifor (pasireotide diaspartate) has been approved by the U.S. Food and Drug Administration to treat Cushing's disease in cases that cannot be treated by surgery. Cushing's occurs when the body overproduces cortisol, a hormone made by the adrenal glands. Cortisol helps regulate the body's reaction to stress and injury. People with Cushing's may be overweight, glucose intolerant, diabetic, have high blood pressure, bruise easily and be at increased risk of infection, the agency said in a news release. Signifor was evaluated in a clinical study of 162 people with Cushing's disease, and a reduction in cortisol production was seen in as little as one month. About 20 percent of people had cortisol levels within the normal range by the end of the six-month study, the FDA said. The most common adverse reactions to the twice-daily injected drug included high blood sugar, ... Read more

Related support groups: Cushing's Syndrome

FDA Approves Signifor, a New Orphan Drug for Cushing’s Disease

Posted 17 Dec 2012 by Drugs.com

December 14, 2012 – The U.S. Food and Drug Administration today approved Signifor (pasireotide diaspartate) injection for the treatment of Cushing’s disease patients who cannot be helped through surgery. Cushing’s disease is caused by over-production of cortisol, a hormone made by the adrenal glands. A tumor in the pituitary gland leads to overstimulation of the adrenal gland, which results in excess cortisol production. Cortisol regulates many important functions in the body, including response to stress and injury. Patients with Cushing’s disease may have increased weight, glucose intolerance or diabetes, high blood pressure, easy bruising, and increased risk for infections. “Although surgery tends to be first line therapy to treat Cushing’s disease, Signifor is a new treatment option for patients when surgery hasn’t worked or isn’t an option,” said Mary Parks, M.D., director of th ... Read more

Related support groups: Cushing's Syndrome, Cushing's Syndrome, exogenous, Cushing's Syndrome, ectopic

Experimental Drug Shows Promise Against Cushing's Disease

Posted 7 Mar 2012 by Drugs.com

WEDNESDAY, March 7 – An experimental drug called pasireotide reduced levels of the "stress hormone" cortisol and improved symptoms in patients with Cushing's disease, a new study found. Cushing's disease is a rare (three to five cases per million people) hormonal disorder that causes a wide range of health problems and, if untreated, significantly increases a patient's risk of dying at a much younger age than normal, researchers said in a news release. Weight gain, high blood pressure, mood swings, irregular or absent menstrual periods, insulin resistance, glucose intolerance and type 2 diabetes are among the symptoms of Cushing's disease. It is a form of Cushing's syndrome, which is caused by prolonged exposure of the body's tissues to high levels of the hormone cortisol. This phase 3 study of 162 patients in 18 countries found that treatment with pasireotide reduced cortisol ... Read more

Related support groups: Cushing's Syndrome

Korlym Approved for Cushing's Syndrome

Posted 20 Feb 2012 by Drugs.com

MONDAY, Feb. 20 – Korlym (mifepristone) has been approved by the U.S. Food and Drug Administration to treat endogenous Cushing's syndrome, a disabling disorder caused by overproduction of the so-called "stress hormone," cortisol. Cortisol is produced by the adrenal glands and increases blood sugar, making it particularly dangerous for people with diabetes. Korlym does not decrease production of the hormone, but reduces the effects of overproduction, the FDA said in a news release. The approval is for people with endogenous (of internal cause) Cushing's syndrome who have type 2 diabetes and who either haven't responded to previous surgery or aren't candidates for new surgery. Only about 5,000 people in the United States are likely to be eligible for the drug, the agency said. The medication was evaluated in clinical studies involving 50 people. Participants who took Korlym had ... Read more

Related support groups: Mifepristone, Cushing's Syndrome, Mifeprex

FDA Approves Korlym for Patients with Endogenous Cushing's Syndrome

Posted 17 Feb 2012 by Drugs.com

FRIDAY, February 17, 2012 – Today, Korlym (mifepristone) was approved by the U.S. Food and Drug Administration to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing’s syndrome. This drug was approved for use in patients with endogenous Cushing’s syndrome who have type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to prior surgery. Korlym should never be used (contraindicated) by pregnant women. Prior to FDA’s approval of Korlym, there were no approved medical therapies for the treatment of endogenous Cushing’s syndrome. Endogenous Cushing’s syndrome is a serious, debilitating and rare multisystem disorder. It is caused by the overproduction of cortisol (a steroid hormone that increases blood sugar levels) by the adrenal glands. This syndrome most commonly affects adults between the ages of 25 and 40. About ... Read more

Related support groups: Cushing's Syndrome

Ask a Question

Further Information

Related Drug Support Groups

dexamethasone, cyproheptadine, Periactin, Decadron, mifepristone, Korlym, Dexpak Taperpak, Signifor, Acthrel, view more... Adrenocot, Adrenocot LA, Dexone, pasireotide, Cytadren, Baycadron, Dalalone, Dexamethasone Intensol, Hexadrol, Dalalone DP, Dalalone LA, corticorelin, Zema Pak, Decaject LA, Decaject, Decadron-LA, Solurex LA, Dexasone, Dexasone LA, Dexacort-LA, De-Sone LA, Dexacen-4, aminoglutethimide, Dexone LA, Medidex LA, Medidex, Dexacorten, Primethasone, Solurex